Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.50 |
| ▸ | SQLE | Q14534 | 4/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954111 | 1.00 | KMT2A (0.56) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| SCHEMBL530927 | 0.96 | KMT2A (0.64) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| SCHEMBL7757953 | 0.96 | KMT2A (0.64) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| SCHEMBL530928 | 0.96 | KMT2A (0.64) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| SCHEMBL11436605 | 0.83 | BTN3A1 (0.44) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| SCHEMBL11436601 | 0.83 | BTN3A1 (0.44) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| Squalene SCHEMBL27987791 | 0.81 | KMT2A (0.85) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| SCHEMBL8702915 | 0.78 | SQLE (0.43) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| SCHEMBL8702913 | 0.78 | SQLE (0.43) | KMT2AALDH1A1ALOX15MEN1CYP3A4 | |
| SCHEMBL1472323 | 0.77 | KMT2A (0.56) | KMT2AALDH1A1ALOX15MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800790-B2 | Sesquiterpenoid STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2020-10-13 | — | — | US | claimed |
| US-9901565-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | PROTECTEA, LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| EP-2460405-B1 | EPIGALLOCATECHIN GALLATE DERIVATIVE AS ANTIBACTERIAL AGENT | UNIV OSAKA (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8952055-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2460405-A1 | ANTIBACTERIAL AGENT | Osaka University (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | KAIHATSU, Kunihiro (JP) | 2011-01-06 | — | — | US | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800790-B2 | Sesquiterpenoid STAT3 inhibitors | STAT3, JAK2, STAT6 | KMT2A 1799/4885ALDH1A1 1903/4885ALOX15 2608/4885 |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | TEAD4, ELOVL6, TEAD1 | KMT2A 1258/4885ALDH1A1 677/4885ALOX15 1055/4885 |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | KMT2A 2118/4885ALDH1A1 2332/4885ALOX15 1986/4885 |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | KMT2A 2118/4885ALDH1A1 2332/4885ALOX15 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.